Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
625 stopped studies mapped to Malignant Urinary System Neoplasm and descendants · 88% state a reason
Over the 625 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01740154 | Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer | N/A | terminated | Dec 4, 2012 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT00540969 | Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone… | Phase 3 | terminated | Oct 8, 2007 | Alliance for Clinical Trials in Oncology | Low accrual | Enrollment / accrual |
| NCT00126659 | Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer | Phase 2 | terminated | Aug 4, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02334527 | Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure… | Phase 2 | terminated | Jan 8, 2015 | UNC Lineberger Comprehensive Cancer Center | Data from first 12 subjects-primary endpoint not met. Data analysis underway. | Other (stated, no rule matched) |
| NCT03693573 | A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or… | Phase 3 | withdrawn | Oct 3, 2018 | Hoffmann-La Roche | In the context of the ongoing evaluation of our data, we have determined that there is no need to… | Safety / toxicity |
| NCT03226236 | Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination…(RENALVax-2) | Phase 2 | withdrawn | Jul 21, 2017 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | No patients enrolled due to change in standard practice | Enrollment / accrual |
| NCT02669914 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | Phase 2 | terminated | Feb 1, 2016 | Washington University School of Medicine | Low accrual, funding withdrawn by AstraZeneca, and change in clinical practice | Enrollment / accrual |
| NCT03208712 | Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases… | Early Phase 1 | terminated | Jul 5, 2017 | University of Michigan Rogel Cancer Center | Low accrual | Enrollment / accrual |
| NCT02560012 | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | Phase 2 | terminated | Sep 25, 2015 | The University of Texas Health Science Center, Houston | Loss of laboratory performing molecular analysis | Other (stated, no rule matched) |
| NCT02763761 | An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus… | Phase 2 | withdrawn | May 5, 2016 | Bristol-Myers Squibb | Insufficient enrollment | Enrollment / accrual |
| NCT02605863 | Enzalutamide for Bladder Cancer Chemoprevention | Phase 2 | terminated | Nov 16, 2015 | University of Rochester | Low enrollment, sponsor withdrew support for study | Enrollment / accrual |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic,… | Phase 1 | terminated | Jan 8, 2016 | Mayo Clinic | permanently closed per sponsor's request | Other (stated, no rule matched) |
| NCT02145390 | Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant… | N/A | terminated | May 22, 2014 | University of Miami | Investigator Decision - Insufficient Accrual | Investigator |
| NCT02700724 | Observation Versus Immediate Surgery of Low Risk Bladder Cancer | N/A | terminated | Mar 7, 2016 | Vanderbilt University Medical Center | poor enrollment | Enrollment / accrual |
| NCT01453465 | Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or… | — | withdrawn | Oct 17, 2011 | Children's Oncology Group | not stated | Not stated |
| NCT01642095 | Studying Biomarkers in Samples From Younger Patients With Kidney Cancer | — | withdrawn | Jul 17, 2012 | Children's Oncology Group | not stated | Not stated |
| NCT02386111 | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell… | Phase 1 | terminated | Mar 11, 2015 | Celldex Therapeutics | Portfolio re-prioritization | Sponsor / business decision |
| NCT00089102 | Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or… | Phase 2 | terminated | Aug 5, 2004 | Medical University of South Carolina | Low accrual | Enrollment / accrual |
| NCT00089128 | Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic… | Phase 2 | terminated | Aug 5, 2004 | Medical University of South Carolina | Low accrual | Enrollment / accrual |
| NCT00090870 | PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With… | Phase 2 | terminated | Sep 8, 2004 | Medical University of South Carolina | Pharmaceutical collaborator pulled funding. | Funding |
| NCT00268450 | Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel… | Phase 2 | terminated | Dec 22, 2005 | Medical University of South Carolina | not stated | Not stated |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | Phase 1 / Phase 2 | terminated | Apr 22, 2015 | Western Regional Medical Center | Investigator no longer at site to enroll patients or write up data | Investigator |
| NCT01482949 | A Rollover Protocol for Subjects Previously Treated With AGS-003 | Phase 2 | terminated | Dec 1, 2011 | Argos Therapeutics | Lack of efficacy | Efficacy / futility |
| NCT02626754 | A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell… | Phase 2 | terminated | Dec 10, 2015 | vghtpe user | In most sites had difficult to recruitting subjects. | Enrollment / accrual |
| NCT03149159 | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation… | Phase 2 | withdrawn | May 11, 2017 | Medical University of South Carolina | This study is withdrawn due to feasibility issues. | Other (stated, no rule matched) |
| NCT01582672 | Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of…(ADAPT) | Phase 3 | terminated | Apr 23, 2012 | Argos Therapeutics | Lack of efficacy | Efficacy / futility |
| NCT03106610 | Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With… | Phase 1 | terminated | Apr 10, 2017 | M.D. Anderson Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT02511275 | Nephrotoxicity Associated to Parenchymal Clamping During Partial Nephrectomy Using a…(NECPAR) | N/A | terminated | Jul 30, 2015 | Centre Hospitalier Universitaire de Saint Etienne | this type of surgery is now performed with a surgical robot that no longer allows the realization… | Other (stated, no rule matched) |
| NCT02471495 | RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE) | Phase 3 | withdrawn | Jun 15, 2015 | Medical Enterprises Europe B.V. | not stated | Not stated |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Phase 1 | terminated | Sep 7, 2015 | Celldex Therapeutics | Portfolio re-prioritization | Sponsor / business decision |
| NCT02747173 | Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and…(METHEOS) | — | terminated | Apr 21, 2016 | Spanish Oncology Genito-Urinary Group | not stated | Not stated |
| NCT01331824 | Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory… | Phase 2 | terminated | Apr 8, 2011 | Matthew Galsky | due to a development decision by the funder | Other (stated, no rule matched) |
| NCT01234519 | A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed… | Phase 1 / Phase 2 | terminated | Nov 4, 2010 | AEterna Zentaris | Poor recruitment | Enrollment / accrual |
| NCT03456401 | Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)(TOKIO) | Phase 2 | terminated | Mar 7, 2018 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | availability of new and more promising therapeutic agents than expected in the experimentation in… | Other (stated, no rule matched) |
| NCT02962804 | Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma… | Phase 2 | withdrawn | Nov 11, 2016 | University of Kansas Medical Center | Due to competing trials. Stopped before IRB approval. | Other (stated, no rule matched) |
| NCT01710293 | Intervention Protocol for Automated Point-of-Care Surveillance of Outpatient Delays in…(PACT CREATE 3) | N/A | withdrawn | Oct 19, 2012 | VA Office of Research and Development | Unable to obtain data needed to run the RCT; project never began recruitment | Enrollment / accrual |
| NCT01931462 | Microwave Coagulation in Partial Nephrectomy Protocol | N/A | terminated | Aug 29, 2013 | University of Wisconsin, Madison | Slow enrollment | Enrollment / accrual |
| NCT02845050 | Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With…(JaNEO) | Phase 1 / Phase 2 | withdrawn | Jul 27, 2016 | Ligartis GmbH | No participants found | Other (stated, no rule matched) |
| NCT02338570 | Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With…(ORCHIDEE) | Phase 4 | terminated | Jan 14, 2015 | Mario Negri Institute for Pharmacological Research | Stopped on November 16th 2016, because of recruitment failure. | Enrollment / accrual |
| NCT01826097 | Improving Sensitivity of Urine Cytology for Bladder Cancer | N/A | withdrawn | Apr 8, 2013 | Johns Hopkins University | not stated | Not stated |
| NCT02514408 | Circulating Tumor Cells in Operative Blood in Patients With Bladder Cancer | — | withdrawn | Aug 3, 2015 | University of Southern California | No funding | Funding |
| NCT03238664 | Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for… | N/A | withdrawn | Aug 3, 2017 | University of Southern California | No funding | Funding |
| NCT01012362 | Study of Pazopanib and Ixabepilone in Patients With Solid Tumors | Phase 1 | terminated | Nov 13, 2009 | Masonic Cancer Center, University of Minnesota | PI left institution. | Investigator |
| NCT01762592 | REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With… | Phase 3 | withdrawn | Jan 7, 2013 | Heidelberg Pharma AG | new sponsor | Other (stated, no rule matched) |
| NCT02370342 | Robot-Assisted Ultrasound for Thermal Ablative Therapy in Treating Patients With Small… | N/A | withdrawn | Feb 24, 2015 | University of Southern California | No funding | Funding |
| NCT01469221 | Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive… | Phase 3 | terminated | Nov 10, 2011 | Spectrum Pharmaceuticals, Inc | Business reason | Sponsor / business decision |
| NCT00769990 | Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone… | Phase 1 / Phase 2 | withdrawn | Oct 9, 2008 | Masonic Cancer Center, University of Minnesota | No patient accrual. | Enrollment / accrual |
| NCT00623077 | MT2004-30: Tomotherapy for Solid Tumors | Phase 1 | terminated | Feb 25, 2008 | Masonic Cancer Center, University of Minnesota | Replaced by another study | Other (stated, no rule matched) |
| NCT00003926 | Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | Phase 1 | terminated | May 2, 2003 | Masonic Cancer Center, University of Minnesota | Withdrawn due to slow accrual | Enrollment / accrual |
| NCT02122003 | Second Line Sorafenib After Pazopanib in Patients With RCC(SOAP) | Phase 2 | terminated | Apr 24, 2014 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | availability of new and more promising therapeutic agents than expected in the experimentation in… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Dec 6, 2018source: clinicaltrials